|
New data show treatment of multiple sclerosis with AVONEX enhances quality of life
April 17, 2008Results from a one-year prospective, observational study conducted to determine the impact of beginning treatment with AVONEX on MS patients' overall quality of life (QoL) were announced today. The data showed that patients receiving treatment with AVONEX experienced statistically significant improvements in QoL, as measured by the EuroQol questionnaire (EQ-5D), compared to baseline. In addition, the study demonstrated the negative impact of disability progression (as measured by the expanded disability status scale (EDSS)) on employment status and QoL. These data were presented today as a poster presentation at the 60th American Academy of Neurology annual meeting in Chicago, Illinois.
Led by Dr. Norman Putzki at the University of Duisburg-Essen, in Essen, Germany, and Professor Hans-Peter Hartung at Heinrich-Heine University in Dusseldorf, Germany, the prospective, observational, open label, multicenter study, analyzed 1,157 patients with RRMS, who had received no immunomodulatory therapy within the preceding 12 months before beginning the study. Upon commencement of the study, patients received 30 mcg AVONEX once-weekly and were examined at five data-points over a period of 12 months (at study initiation, after three, six, nine and 12 months). Apart from relapse rate and EDSS scores, QoL was measured by means of EQ-5D, as well as the participation in training for injection, the influence of injection training on the therapeutic behavior and further parameters.
The study demonstrates the importance of treatment with AVONEX in patients with relapsing remitting multiple sclerosis (RRMS), showing the ability to slow disability progression, reduce relapses, and improve QoL. The study results also indicated that:
* Over 90 percent of patients felt an improvement or noticed no reduction in their general health while on AVONEX.
* Mean EDSS score remained practically unchanged over the 12-month treatment period (2.06 at baseline and 2.14 at the 12-month visit; p=0.233).
* Injection training and care through a nurse service was found to improve handling of side effects in nearly 60 percent of patients.
"These data reinforce that AVONEX provides patients with the ability to delay disability progression and shows that effective treatment with AVONEX may enhance QoL," said Dr. Norman Putzki, primary study author, Department of Neurology, University of Duisburg-Essen, Germany.
"As a company, we are committed to providing efficacious treatment options such as AVONEX in an effort to help improve the quality of life of MS patients," said Thorsten Eickenhorst, MD, Vice President of Medical Affairs at Biogen Idec.
AVONEX is the number one prescribed treatment for relapsing forms of multiple sclerosis (MS) worldwide, and is the only once-a-week MS therapy that is proven after the first attack. AVONEX is also proven to slow the progression of physical disability (as shown by 37 percent reduction over two years) and reduce the number of relapses. Nearly nine out of 10 patients remained fully functional after five years. AVONEX has been proven effective in clinical trials for up to three years.
Manning Selvage & Lee
* Over 90 percent of patients felt an improvement or noticed no reduction in their general health while on AVONEX.
* Mean EDSS score remained practically unchanged over the 12-month treatment period (2.06 at baseline and 2.14 at the 12-month visit; p=0.233).
* Injection training and care through a nurse service was found to improve handling of side effects in nearly 60 percent of patients.
"These data reinforce that AVONEX provides patients with the ability to delay disability progression and shows that effective treatment with AVONEX may enhance QoL," said Dr. Norman Putzki, primary study author, Department of Neurology, University of Duisburg-Essen, Germany.
"As a company, we are committed to providing efficacious treatment options such as AVONEX in an effort to help improve the quality of life of MS patients," said Thorsten Eickenhorst, MD, Vice President of Medical Affairs at Biogen Idec.
AVONEX is the number one prescribed treatment for relapsing forms of multiple sclerosis (MS) worldwide, and is the only once-a-week MS therapy that is proven after the first attack. AVONEX is also proven to slow the progression of physical disability (as shown by 37 percent reduction over two years) and reduce the number of relapses. Nearly nine out of 10 patients remained fully functional after five years. AVONEX has been proven effective in clinical trials for up to three years.
Manning Selvage & Lee
Multiple Sclerosis News and Current Multiple Sclerosis Events RSSNew Guidelines for Treating Rheumatoid Arthritis
Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB).
Milestone for cannabinoid MS study
The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School in Plymouth has reached an important milestone with the news that the full cohort of 493 people with multiple sclerosis (MS) has been recruited to the study.
Statins have unexpected effect on pool of powerful brain cells
Cholesterol-lowering drugs known as statins have a profound effect on an elite group of cells important to brain health as we age, scientists at the University of Rochester Medical Center have found. The new findings shed light on a long-debated potential role for statins in the area of dementia.
Best treatment for MS may depend on disease subtype
Animal studies by University of Michigan scientists suggest that people who experience the same clinical signs of multiple sclerosis (MS) may have different forms of the disease that require different kinds of treatment.
Medicines derived from cannabis: a review of adverse events
Researchers at the McGill University Health Centre (MUHC), McGill University and the University of British Columbia (UBC) determined that medical use of cannabinoids do not cause an increase in serious adverse events, but are associated with an increase in some non-serious adverse events.
Developing unique brain maps to assist surgery and research
Researchers from the Howard Florey Institute in Melbourne are developing new technology to create individualised brain maps that will revolutionise diagnosis of disease and enhance the accuracy of brain surgery.
Immune molecule that plays a powerful role in avoiding organ rejection identified
When a mouse's immune system is deciding whether to reject a skin graft, one powerful member of a molecular family designed to provoke such a response can effectively reduce the visibility of the mouse's own cells and help the graft survive, researchers say.
EuroDYNA takes lid off the genome
European researchers have made significant progress unravelling how genes are governed and why this sometimes goes wrong in disease.
'HiCy' drug regimen reverses ms symptoms in selected patients
A short-term, very-high dose regimen of the immune-suppressing drug cyclophosphamide seems to slow progression of multiple sclerosis (MS) in most of a small group of patients studied and may even restore neurological function lost to the disease, Johns Hopkins researchers report.
Human stem cells show promise against fatal children's diseases
Scientists have used human stem cells to dramatically improve the condition of mice with a neurological condition similar to a set of diseases in children that are invariably fatal, according to an article in the June issue of the journal Cell Stem Cell.
More Multiple Sclerosis News Articles
 | The MS Recovery Diet by Ann Sawyer, Judith Bachrach |
 | Living Well: 21 Days to Transform Your Life, Supercharge Your Health, andFeel Spectacular by Montel Williams, William Doyle |
 | The Multiple Sclerosis Diet Book by Roy Laver Swank, Barbara Brewer Dugan |
 | Exercises for Multiple Sclerosis: A Safe and Effective Program to Fight Fatigue, Build Strength, and Improve Balance (Exercises for) by Brad Hamler |
 | Multiple Sclerosis For Dummies (For Dummies (Health & Fitness)) by Rosalind, Ph.D. Kalb, Nancy, RN, EdD, MSCN Holland, Barbara, MD Giesser |
 | Complementary and Alternative Medicine and Multiple Sclerosis by Allen C. Bowling |
 | The MS Workbook: Living Fully With Multiple Sclerosis by George H., M.D. Kraft, Dawn M., Ph.D. Ehde, Kurt L., Ph.D. Johnson |
 | The First Year: Multiple Sclerosis: An Essential Guide for the Newly Diagnosed (The First Year) by Margaret Blackstone |
 | Blindsided: Lifting a Life Above Illness: A Reluctant Memoir by Richard M. Cohen |
 | The Fiction Class by Susan Breen |
| © 2008 BrightSurf.com |